Optimal usage of dual trigger to prevent OHSS in a long-protocol IVF cycle

Jung, Yoon-Hee; Kim, Y.Y.; Kim, M.H.; Yoo, Young-Geun; Jo, J.D.

doi:10.1016/j.fertnstert.2014.07.748

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, a novel strategy to modify ovulation triggering through the use of a bolus of GnRH agonist plus a reduced or standard dosage of hCG (dual trigger) was proposed ( Shapiro et al ., 2011 ; Griffin et al ., 2014 ; Jung et al ., 2014 ; Kim et al ., 2014 ; O’Neill et al ., 2016 ). The rationale behind this strategy was that triggering with a GnRH agonist would effectively minimize the risk of OHSS, while the added hCG would also preserve adequate luteal function.…”

Section: Introductionmentioning

confidence: 99%

GnRH agonist in association with hCG versus hCG alone for final oocyte maturation triggering in GnRH antagonist cycles

Filho¹,

Oliveira²,

Fonseca³

et al. 2021

JBRA Assisted Reproduction

View full text Add to dashboard Cite

Objective: To analyze gonadotropin-releasing hormone (GnRH) agonist in association with human chorionic gonadotropin (hCG) (dual triggering) versus hCG alone (conventional triggering) for final oocyte maturation triggering in GnRH antagonist cycles in an unselected population of Brazilian women. Methods: This prospective case-control study involved 114 patients referred to autologous in vitro fertilization treatment between February 2018 and August 2019, recruited regardless of age, infertility factor or number of cycles. The patients were randomly allocated into two groups according to oocyte maturation triggering approach: group A (n = 48) - hCG only; and group B (n = 66) - hCG plus GnRH agonist. The main outcomes measured were the number of total and metaphase II (MII) oocytes retrieved. Results: The groups were homogenous in terms of age. There were no moderate or severe ovarian hyperstimulation syndrome events. There were no statistical differences concerning total or MII oocytes retrieved between the groups ( p > 0.05). The MII/total oocyte rate was 70.9% in group A, and 74.5% in group B ( p = 0.679). There was no oocyte retrieved in 2/48 patients (4.16%) in group A, 1/66 (1.5%) in group B. There were no MII oocytes in 4/48 patients (8.3%) in group A, and 2/66 (3%) in group B. Age was directly correlated to the number of total and MII oocytes retrieved ( p < 0.05). Conclusions: Dual triggering was equivalent to conventional hCH triggering in terms of the number of total and MII oocytes retrieved in the general population. Further studies are necessary to ascertain dual triggering indication in selected groups of women.

show abstract

Section: Introductionmentioning

confidence: 99%

GnRH agonist in association with hCG versus hCG alone for final oocyte maturation triggering in GnRH antagonist cycles

Filho¹,

Oliveira²,

Fonseca³

et al. 2021

JBRA Assisted Reproduction

View full text Add to dashboard Cite

show abstract

“…Even though benefits were shown when using the dual triggering regimen in high-responder and normal-responder patients or having oocyte immaturity, few studies have been performed to show the effects when using this regimen in the poor-responder population ( 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 ).…”

Section: Introductionmentioning

confidence: 99%

Dual trigger with gonadotropin-releasing hormone and human chorionic gonadotropin for poor responders

Eser

Devranoğlu

Ergen

et al. 2018

J Turkish German Gynecol Assoc

View full text Add to dashboard Cite

Objective:To compare metaphase II (MII) rate, fertilization rate, and embryo quality with dual trigger gonadotropin-releasing hormone agonist (GnRH) and normal dose human chorionic gonadotropin (hCG) versus a normal dose hCG trigger in antagonist intracytoplasmic sperm injection (ICSI) cycles of poor ovarian responders.Material and Methods:Patients defined as poor ovarian responders according to the Bologna criteria who underwent ICSI with GnRH antagonist protocol and triggered with dual trigger or hCG alone for oocyte maturation. Main outcome measures were MII rate, fertilization rate, and embryo quality.Results:Total gonadotropin doses and E2 levels on trigger day were higher in the hCG trigger group. There were no significant differences with regard to implantation rate (p=0.304), biochemical pregnancy rate (p=0.815), clinical pregnancy rate (p=0.378), and ongoing pregnancy rate (p=0.635) between the groups.Conclusion:Dual trigger of oocyte maturation with GnRH agonist and normal dose hCG in poor responders does not demonstrate improved oocyte maturation, clinical pregnancy, and ongoing pregnancy rates.

show abstract

Optimal usage of dual trigger to prevent OHSS in a long-protocol IVF cycle

Cited by 2 publications

References 0 publications

GnRH agonist in association with hCG versus hCG alone for final oocyte maturation triggering in GnRH antagonist cycles

GnRH agonist in association with hCG versus hCG alone for final oocyte maturation triggering in GnRH antagonist cycles

Dual trigger with gonadotropin-releasing hormone and human chorionic gonadotropin for poor responders

Contact Info

Product

Resources

About